Table 4 Logistic regression analysis to identify patients harboring the T790M substitution among those with EGFR-mutated lung cancer (n = 53)

Mutation site at initial diagnosis; Exon 19 Deletion vs. L858R

0.17

0.05–0.51

0.002

0.04

0.004–0.34

0.003

Reason for termination of TKIs;

2.26

1.25–4.11

0.007

3.65

1.39–9.59

0.008

 Ongoing

 AEs

1

–

–

1

–

–

 Tumor growth

37.3

3.30–421.6

0.003

33.8

1.60–713.3

0.024

 New lesions

12.4

1.32–117.0

0.027

44.9

2.13–950.9

0.014

Medical Drugs at TKI-naïve line

0.24

0.08–0.72

0.01

0.09

0.01–0.62

0.014

 Gefitinib

 Erlotinib

0.18

0.035–0.95

0.044

0.49

0.02–0.99

0.049

 Afatinib

0.06

0.007–0.55

0.012

0.01

0.0002–0.53

0.02

Chemotherapy; absent vs. present

2.63

0.84–8.22

0.09

“Serum level of CEA at progression” divided by “Serum nadir level of CEA”

1.16

0.97–1.39

0.11

1.22

0.77–1.93

0.4

Serum nadir level of CEA (ng/mL)

0.97

0.95–1.01

0.14